Guangzhou Medical University

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Huichao Liang, An Expert on AIDS Combined with Gynecological Oncology, Receives Excellent Popular Science Worker Award

Retrieved on: 
Friday, February 24, 2023
Guangzhou Medical University, Bacteria, STD, HIV/AIDS denialism, Control, Female, HIV, People's Hospital, Pragathi Nagar, Human papillomavirus infection, World Health Organization, Diagnosis, Pregnancy, Gynaecology, Ovarian cancer, Research, California Community College Athletic Association, Hospital, Obstetrics, International Society, HIV/AIDS, CDC classification system for HIV infection, Survival rate, Syphilis, Conditional sentence, L-theory, Patient, Hepatitis B, Endometrial cancer, WHO, AIDS, Hysterectomy, Committee, Fungal infection, Meta-analysis, HPV, Science, Infection, Multimedia, Traditional Chinese characters, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Cervical cancer, Tuberculosis, Health, Birth control, Vaccine, Pharmaceutical industry

Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.

Key Points: 
  • Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.
  • How to improve the survival rate and cure rate of gynecological tumor patients is the focus of research of gynecological oncology experts at home and abroad.
  • Huichao Liang spent a lot of time and energy on the integration and improvement of the medical team.
  • As an infectious disease combined with gynecological oncology expert, Huichao Liang must face the terrible viruses and bacteria and defeat them with wisdom.

New Study Shows Virtual Bronchoscopic Navigation With Fused Fluoroscopy and Vessel Mapping Using Broncus Archimedes System is Safe and Effective in Obtaining High Biopsy Yield in Lung Tumors

Retrieved on: 
Friday, March 25, 2022
Biotechnology, Health, Surgery, Oncology, Risk, Blood, Marketing, Therapy, Cell, Lung, Temple University Hospital, Diagnosis, First Affiliated Hospital of Xinjiang Medical University, Biopsy, Archimedes, University of Pennsylvania, Shanghai Chest Hospital, Pulmonology, Planner, Respiratory disease, Pneumothorax, VBN, TBNA, Â, MD, Houston Methodist Hospital, Temple University, Fluoroscopy, Trial of the century, Beth Israel Deaconess Medical Center, Chair, Degenerative disease, Guangzhou Medical University, Lung cancer, University, Patient, Medical device, Medical imaging, Medicine

The prospective, single-arm, multicenter study of 104 patients studied biopsy yield (biopsy forceps and/or needle), sampling yield (including cytologic sampling) and diagnostic yield using the Archimedes System to guide bronchoscopic transparenchymal nodule access (BTPNA) and guided transbronchial needle aspiration (TBNA).

Key Points: 
  • The prospective, single-arm, multicenter study of 104 patients studied biopsy yield (biopsy forceps and/or needle), sampling yield (including cytologic sampling) and diagnostic yield using the Archimedes System to guide bronchoscopic transparenchymal nodule access (BTPNA) and guided transbronchial needle aspiration (TBNA).
  • The Archimedes VBN System combines fused fluoroscopy, real-time bronchoscopy and virtual bronchoscopic navigation for 3D views and access to nodules anywhere in the lung, with the ability to avoid major blood vessels through vessel mapping.
  • In this study, BTPNA showed a superior biopsy yield when compared to todays bronchoscopic diagnostic approaches.
  • Its lung cancer diagnostic and therapeutic portfolio includes the Archimedes System, Archimedes Lite Virtual Bronchoscopic Navigation (VBN) System, Archimedes Planner and FleXNeedle.

Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect

Retrieved on: 
Wednesday, November 3, 2021
People, Coronavirus, Research, Artemisinin, National Medical Products Administration, Guangzhou University, Guangzhou Medical University, Disease, Association, Tablet, Firestone Institute for Respiratory Health, Guangzhou University of Chinese Medicine, Infection, Joint Medical Service (Germany), TCM, Efficacy, National Health Commission, Genetics, Malaria, Hospital, Social media, International Journal of Antimicrobial Agents, COVID-19, Safety, Antimicrobial, Xinhui People's Hospital, Observation, Artemisia annua, Treatment, Canadian International Council, Pharmaceutical industry

These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".

Key Points: 
  • These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".
  • This implies how the scientific community and the general public are in desperate need of effective drug treatments for COVID-19.
  • And they have been the drug of first choice recommended by the National Health Commission of China since 2009.
  • Going ahead, the drug is expected to have a greater role to play in the treatment of other diseases," said Zhu Layi, president of Guangdong New South Group.

Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and 'Psychedelic Concierge' Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental Health

Retrieved on: 
Thursday, October 14, 2021
Risk, Pharmacology, Telehealth, FWB, Adrienne Arsht Center for the Performing Arts, State University of New York, Korea University, Lists of diseases, SUNY, State University of New York Upstate Medical University, Ketamine, State university system, Ta' Braxia Cemetery, CSE, OTC, Depression, Drug prohibition law, Ibogaine, PTSD, Guangzhou Medical University, Meditation, Addiction, The New York Times, FDA, Multimedia, News, Removal of cannabis from Schedule I of the Controlled Substances Act, University, CDSA, Health Canada, Clarivate, Forward-looking statement, Company, National Basketball Association, Psychiatry, College, Transitive dependency, Person, Controlled Drugs and Substances Act, Psilocybin, Anxiety, Euro-Excellence Inc v Kraft Canada Inc, Disorder, Rapids, Consciousness, Pharmaceutical industry, Audit

As a world-leading depression researcher, Dr. Roger McIntyre has been named one of the world's most influential scientific minds by Clarivate for seven consecutive years.

Key Points: 
  • As a world-leading depression researcher, Dr. Roger McIntyre has been named one of the world's most influential scientific minds by Clarivate for seven consecutive years.
  • Lamar Odom is a two-time National Basketball Association champion, Olympic gold medalist, New York Times bestselling author, and mental health advocate.
  • Zappy Zapolin is the co-founder and executive chairman of KetaMD , a developing telemedicine platform that provides at-home medical ketamine treatments.
  • "Dr. McIntyre and I are very mission-aligned on the untapped benefits of psychedelics in the treatment of many mental health conditions," says Zappy Zapolin, co-founder of KetaMD and director of Reborn.

Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

Retrieved on: 
Friday, September 17, 2021
People, WebRTC, Degenerative disease, Wu Zhongchao, Efficiency, Technology, Hematology, Forward-looking statement, MDT, Coronavirus, First Affiliated Hospital of Xinjiang Medical University, Patient, Company, Private Securities Litigation Reform Act, Microbiology, Second Affiliated Hospital of Xinjiang Medical University, Disease, Human, Physician, Infection, Medicine in China, Hospital, NASDAQ, Solution, Growth, Chinese Medical Doctor Association, Neoplasm, Review, Learning, Lists of diseases, Guangzhou Medical University, Diagnosis, Goal, SEC, Cancer, 301 Hospital, Chongqing Medical University, Ruijin Hospital, Medicine, Public relations

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").

Key Points: 
  • SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").
  • The Hematology MDT Platform provides clinicians with a channel to learn multidisciplinary thinking skills online, in order to improve diagnosis and treatment and further the efficiency of treatment.
  • In addition, physicians can watch MDT training videos to learn the clinical thinking skills from experts and improve their problem-solving ability during the disease diagnosis and treatment.
  • Zhongchao's Hematology MDT platform provides physicians with a convenient and rapid access to learn and exchange MDT practices and experiences andwill promote the development of hematology treatment models in China.